Part two of this article series shows how traditional statistical process control rules can be relaxed or adjusted to allow charting and evaluation of real-life data of pharmaceutical processes with a reduced number of false alarms.
IAMCHAMP - STOCK.ADOBE.COM
Part two of this article series shows how traditional statistical process control rules can be relaxed or adjusted to allow charting and evaluation of real-life data of pharmaceutical processes with a reduced number of false alarms. Ten practical tools or measures are suggested for minimizing false alarms among process data plotted as is on charts, provided concurrent process performance and product quality are demonstrated. This pragmatic approach reduces the number of futile investigations of apparent innocuous process deviations and streamlines the implementation of the third process validation stage of continued process verification or ongoing process verification.
Click here for a PDF of the article.Click here for a PDF of the article.
Submitted: March 3, 2021
Accepted: May 3, 2021
Raphael Bar, PhD, rbar@netvision.net.il, is a consultant at BR Consulting in Ness Ziona, Israel.
Pharmaceutical Technology
Volume 45, Number 11
November 2021
Pages: 46–53
When referring to this article, please cite it as R. Bar, “Practical SPC Rules in the Real World of an Ongoing Process Verification Plan: Part 2. Practical SPC Rules to Apply on Pharmaceutical Process,” Pharmaceutical Technology 45 (11) 2021.
Get the essential updates shaping the future of pharma manufacturing and compliance—subscribe today to Pharmaceutical Technology and never miss a breakthrough.
A Novel, Enhanced, and Sustainable Approach to Audit Trail Review
July 4th 2025Eli Lilly and Company developed an innovative and sustainable approach to audit trail review (ATR) aimed at reducing the ATR burden while adhering to regulatory expectations and data integrity (DI) principles. The process has transformed employees' understanding of ATR and complemented the DI by design approach, leading to better system designs that meet expected controls and reduce non-value-added data reviews.